Cefazolin

Summary

Cefazolin (CHEMBL1435) is an approved small-molecule antibacterial drug (ATC J01DB04); indicated across 16 conditions including bacterial infectious disease and skin disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DB04
• Indications: 16 conditions
• Clinical trials: 111
• Chemistry: 454.5 Da · C14H14N8O4S3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1435
Name	Cefazolin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	33255
ChEBI	CHEBI:474053
ATC	J01DB04
Molecular formula	C14H14N8O4S3
Molecular weight	454.5
InChIKey	MLYYVTUWGNIJIB-BXKDBHETSA-N

SMILES: CC1=NN=C(S1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CN4C=NN=N4)SC2)C(=O)O

IUPAC name: (6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Cefazolin, Cefazolina, Cefazoline, J01DB04, cefazolin, cefozolin, Cefamezin, SID29215418, SID90340701, SID47193754, CEFAZOLINE, SID144205244

Parent form; salt/anhydrous children: CHEMBL1200523

Patent coverage: 10,564 distinct patent families (37,670 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Fructose-bisphosphate aldolase, Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp, Solute carrier family 22 member 6, Organic anion transporter 3, Solute carrier family 22 member 11, Prostaglandin G/H synthase 2.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC22A6	6.75	Ki	180	nM	CHEMBL_ACT_11002263
SLC22A8	6.26	Ki	550	nM	CHEMBL_ACT_11002293
LMNA	6.05	Potency	891.3	nM	CHEMBL_ACT_3666727
SLC22A11	5.76	Ki	1740	nM	CHEMBL_ACT_11002335

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

16 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
skin disorder	3	MONDO:0005093	EFO:0000701
bacterial infectious disease with sepsis	3	MONDO:0005229	EFO:0003033
cellulitis	3	MONDO:0005230	EFO:0003035
osteomyelitis	3	MONDO:0005246	EFO:0003102
staphylococcus aureus infection	3	MONDO:0005545	EFO:0005681
laryngeal neoplasm	3	MONDO:0021071	MONDO:0002358
gram-positive bacterial infections	3	MONDO:0021679	MONDO:0021679
Clostridium infectious disease	3	MONDO:0024388	EFO:1000874
bone fracture	2	MONDO:0005315	EFO:0003931
injury	2	MONDO:0021178	EFO:0000546
cutaneous melanoma	1	MONDO:0005012	EFO:0000389
obesity disorder	0	MONDO:0011122	EFO:0001073

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 111.

Phase distribution

Phase	Trials
PHASE4	41
Not specified	38
PHASE3	16
PHASE1	9
PHASE2	3
PHASE1/PHASE2	2
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05137119	PHASE4	RECRUITING	Staphylococcus Aureus Network Adaptive Platform Trial
NCT05447559	PHASE4	RECRUITING	Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study
NCT05852158	PHASE4	RECRUITING	Antibiotics for Prevention of Infection Following Orthognathic Surgery
NCT06055712	PHASE4	ENROLLING_BY_INVITATION	Antibiotic Prophylaxis in Pediatric Open Fractures
NCT06567808	PHASE4	NOT_YET_RECRUITING	Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial
NCT06920147	PHASE4	NOT_YET_RECRUITING	PRevention Of Trauma-related Infections Through an Embedded Clinical Trials Network
NCT07549542	PHASE4	ENROLLING_BY_INVITATION	Efficacy and Safety of Intraosseous Antibiotic Prophylaxis in Total Hip Replacement
NCT07608562	PHASE4	NOT_YET_RECRUITING	Azithromycin for Cerclage Prophylaxis
NCT00550290	PHASE4	COMPLETED	Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy
NCT01273818	PHASE4	COMPLETED	Effectiveness of Topical Antibiotic Prophylaxis in Inguinal Hernia Repair
NCT01295606	PHASE4	COMPLETED	Cefazolin Pharmacokinetics: Elimination Clearance in Neonates
NCT01537380	PHASE4	COMPLETED	Tissue and Plasma Pharmacokinetics of Cefazolin in Antibiotic Prophylaxis in Bariatric Surgery
NCT01613092	PHASE4	COMPLETED	Prevention of Arrhythmia Device Infection Trial (PADIT)
NCT01619982	PHASE4	COMPLETED	Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients
NCT01721616	PHASE4	WITHDRAWN	Comparison Study of Cefazolin Versus Cefazolin Plus Azithromycin Prophylaxis in Post-Cesarean Endometritis
NCT01755026	PHASE4	COMPLETED	Serum and Tissue Cefazolin Concentrations in Patients Undergoing Cesarean Delivery
NCT01880112	PHASE4	WITHDRAWN	Serum and Tissue Cefazolin Concentrations in Normal Weight Patients Undergoing Cesarean Delivery.
NCT01980082	PHASE4	COMPLETED	Antibiotic Prophylaxis for Revision, Clean Head and Neck Surgery
NCT02049944	PHASE4	COMPLETED	Increased Cefazolin During Cesarean Delivery in Obese Population
NCT02292082	PHASE4	COMPLETED	The Combination of Adductor Canal Block and Periarticular Injection. A Novel Technique for Patients Undergoing Total Knee Replacement (ACB PAI)
NCT02307006	PHASE4	UNKNOWN	The Use of Ceftaroline as Surgical Prophylaxis in Surgery With Risk of MRSA Infection
NCT02324166	PHASE4	UNKNOWN	Cefazolin-Lidocaine Combination Solution to Reduce Antibiotic Pain
NCT02433704	PHASE4	WITHDRAWN	Preoperative Antibiotic Dosing for Total Knee Arthroplasty
NCT02446782	PHASE4	COMPLETED	Efficacy and Safety of Prophylactic Use of an Antibiotic for Medical Thoracoscopy
NCT02534961	PHASE4	UNKNOWN	Prophylactic Antibiotics Before RFA for HCC
NCT03094663	PHASE4	COMPLETED	Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI)
NCT03231228	PHASE4	TERMINATED	Safety of 1 g and 2 g of Cefazolin in Pediatric Subjects
NCT03261830	PHASE4	COMPLETED	Antibiotics Usage in Pediatric Orthopaedic Percutaneous Surgery (APOPS)
NCT03283878	PHASE4	COMPLETED	Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial
NCT03402945	PHASE4	COMPLETED	Prevention of Infections in Cardiac Surgery (PICS) Prevena Study
NCT03432858	PHASE4	COMPLETED	Preoperative Antibiotics for Carpal Tunnel Release Surgery
NCT03478163	PHASE4	TERMINATED	Antibiotics During Intrauterine Balloon Tamponade Placement
NCT03560232	PHASE4	TERMINATED	Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens
NCT03675854	PHASE4	WITHDRAWN	Defining the Optimal Duration of Treatment for Low-Risk Peritoneal Dialysis-Related Peritonitis
NCT04141787	PHASE4	UNKNOWN	Ceftriaxone as Home IV for Staph Infections
NCT04303390	PHASE4	COMPLETED	24 Vs 48 Hours of Cefazolin or Cefuroxime as Prophylaxis
NCT04516148	PHASE4	COMPLETED	A Randomized, Controlled Trial of the Effectiveness of Perioperative Antibiotics for Reduction of Burn Wound Bacterial Concentration Following Grafting
NCT04834310	PHASE4	WITHDRAWN	Postoperative Antibiotics Following Primary and Secondary Breast Augmentation
NCT05132829	PHASE4	UNKNOWN	Azithromycin to Improve Latency in Exam Indicated Cerclage Control Trial
NCT05977868	PHASE4	TERMINATED	Comparing Oral Versus Parenteral Antimicrobial Therapy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).